Popular Articles

ImmunoVaccine Technologies Partners With FIT Biotech To Advance A Therapeutic HIV Vaccine
ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development
generic viagra online
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU"s EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS" AFFITOME(R) platform technology. The target is a protein known as CETP (cholesteryl ester transfer protein). Following vaccines for Alzheimer"s disease and Parkinson"s disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.
News of the day
Health Plans Support Consumer Protections
Health plans reiterated their strong support for new market rules and consumer protections to cover all Americans and guarantee coverage for pre-existing conditions.
Public Health

MDS Nordion Opens New Radiopharmaceutical Production Facility In Belgium

MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positron emission tomography (PET) imaging. PET imaging produces a three-dimensional image, or picture, of functional processes in the body, such as brain activity, and is a highly accurate and effective method of diagnosing disease and managing patient therapy. MDS Nordion"s new facility will provide timely supply of F-18 FDG to hospitals throughout Belgium, France, The Netherlands, Luxembourg and Germany. "Customers count on MDS Nordion for leadership, quality products and customized services," said Steve West, President MDS Nordion. "Our investment in this facility further demonstrates our commitment to address the growing demand for PET diagnostic imaging in targeted European regions, and provides the medical community greater service for their future patient care." The PET imaging market is the most rapidly growing area of nuclear medicine and procedures. Statistics from a recent Medical Options survey indicates PET examinations are on a rapid rise in Europe, and are expected to grow at a compound annual rate of approximately 20% through 2012. To help meet increasing demand, this state-of-the-art, Good Manufacturing Practice (GMP) production facility will have three daily production runs and a customer service team available 24 hours a day, seven days a week. "PET imaging is effective because it allows early detection of tumours, as well as assessment of therapeutic strategies," said Professor Roland Hustinx, Nuclear Medicine Department, CHU - Universite de Liege. "In particular, MDS Nordion"s new facility will provide another of supply of F-18 FDG to existing and new medical facilities, thereby increasing the ability of health-care practitioners to conduct this critical type of imaging." MDS Nordion


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):